Cadila Healthcare hits 52-week high on USFDA nod for Clonidine Hcl Injection

Subscribe to GoodReturns

Cadila Healthcare hits 52-week high on USFDA nod for Clonidine Hcl Injection
Shares of drug maker Cadila Healthcare rose nearly 3 per cent, hitting 52-week high, in early trade on Bombay Stock Exchange (BSE) after company announced that it has received the US FDA approval to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.

"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a filing to Bombay Stock Exchange.

Buoyed by development, shares of company gained as much as 2.70 per cent and touched 52-week high to trade at Rs 1022.00 a piece on the BSE.In a similar fashion, shares of the company advanced 1.85 per cent to Rs 1,014.80 a piece on National Stock Exchange.

Meanwhile, the broader benchmark Sensex was quoting at 20,890.91, up 79.47 points or 0.38 per cent at 10:00 hours.

Dion Global Solutions Ltd.

Story first published: Tuesday, February 25, 2014, 12:48 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'